Evidence map›Paper›PMID 31616928›Full record

ArticleThe Journal of infectious diseases2020

A Novel Antiparasitic Compound Kills Ring-Stage Plasmodium falciparum and Retains Activity Against Artemisinin-Resistant Parasites.

Rebecca L Clements, Vincent Streva, Peter Dumoulin, Weigang Huang, Edward Owens, Dipak K Raj, Barbara Burleigh, Manuel Llinás, Elizabeth A Winzeler, Qisheng Zhang and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Current and emerging target identification methods for novel antimalarials.International journal for parasitology. Drugs and drug resistance · 2022
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Rebecca L ClementsBiological and Biomedical Sciences, Harvard Medical School, Boston, Massachusetts, USA.
Vincent StrevaDivision of Infectious Diseases, Boston Children's Hospital, Boston, Massachusetts, USA.
Peter DumoulinDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Weigang HuangDivision of Chemical Biology and Medicinal Chemistry, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Edward OwensHuck Center for Malaria Research, Pennsylvania State University, University Park, Pennsylvania, USA.
Dipak K RajCenter for International Health Research, Rhode Island Hospital, Brown University Medical School, Providence, Rhode Island, USA.
Barbara BurleighDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Manuel LlinásHuck Center for Malaria Research, Pennsylvania State University, University Park, Pennsylvania, USA.
Elizabeth A WinzelerSchool of Medicine, University of California San Diego, La Jolla, California, USA.
Qisheng ZhangDivision of Chemical Biology and Medicinal Chemistry, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Jeffrey D DvorinDivision of Infectious Diseases, Boston Children's Hospital, Boston, Massachusetts, USA.
Harvard University · USBoston Children's Hospital · USPennsylvania State University · USUniversity of North Carolina at Chapel Hill · USRhode Island Hospital · USUniversity of California, San Diego · US

Funding

Molecular mechanisms of schizogony in malaria parasitesR01AI145941 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI DVORIN, JEFFREY D · 2019 to 2023
$3.1M
Molecular characterization and substrate identification of malaria kinase PfCDPK5R01AI102907 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI DVORIN, JEFFREY D · 2014 to 2017
$1.8M
6 · The paper itself

Abstract

Spreading antimalarial resistance threatens effective treatment of malaria, an infectious disease caused by Plasmodium parasites. We identified a compound, BCH070, that inhibits asexual growth of multiple antimalarial-resistant strains of Plasmodium falciparum (half maximal inhibitory concentration [IC50] = 1-2 µM), suggesting that BCH070 acts via a novel mechanism of action. BCH070 preferentially kills early ring-form trophozoites, and, importantly, equally inhibits ring-stage survival of wild-type and artemisinin-resistant parasites harboring the PfKelch13:C580Y mutation. Metabolomic analysis demonstrates that BCH070 likely targets multiple pathways in the parasite. BCH070 is a promising lead compound for development of new antimalarial combination therapy that retains activity against artemisinin-resistant parasites.

Indexed as

AntimalarialsArtemisininsCells, CulturedDrug ResistanceFibroblastsHumansMolecular StructurePlasmodium falciparumStructure-Activity RelationshipTrypanosoma cruziAntimalarialsartemisininArtemisininsantimalarialartemisinin resistancemalariaPlasmodium falciparumring-stage survival

Identifiers

PMID31616928
PMCPMC7050989
OpenAlexW2980573297

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.